Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Role of antigen-specific immunity in BCG therapy for bladder cancer

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
The gold standard immunologic agent for bladder cancer treatment is bacillus Calmette-Guérin (BCG), a live attenuated Mycobacterium. Repeated BCG instillations into bladder significantly reduce recurrence rates and offer an alternative to complete bladder removal. Unfortunately, the relapses occur and when BCG therapy fails, there are few options available. Despite decades of use, the mechanism for BCG efficacy remain largely unknown. Although it is established that T cells are required, the importance of tumor- vs BCG-specific immune response is unknown. Importantly, understanding how BCG augments antigen-specific immunity is critical to developing strategies to avoid BCG failure. We hypothesize that antigen-specific immunity contributes to clinical activity of BCG in bladder cancer. This hypothesis will be tested in the following aims that incorporate mouse models and patient samples to explore mechanisms underlying immune and clinical responses. Aim 1. Test the hypothesis that tumor-specific immunity contributes to BCG efficacy in bladder cancer. We will test effects of BCG on orthotopic bladder tumor-bearing mice by adoptive transfer of naïve vs tumor-specific T cells that we have developed. The effect of BCG on tumor-specific T cells will be corroborated using patient PBMCs before and after BCG treatment. Aim 2. Test the hypothesis that BCG-specific immunity contributes to BCG efficacy in bladder cancer. Similar to Aim 1, we will test BCG-specific T cells in bladder tumor-bearing mice treated with BCG. We will also enrich and transfer human BCG-specific T cells into human-tumor-challenged immune-deficient mice followed by intravesical BCG treatment. Summary: These studies will provide mechanistic insights into BCG efficacy in treating bladder cancer, and help establishing a framework for rapid development of BCG combination strategies for individual patients.
Similar projects All >
Sorted by: Start Date
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Immunization

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science